REFERENCES
1. Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, et al. Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686-721.
2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166:637-48.
3. Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol 2019. Epub ahead of print. doi: 10.1002/hep.31030
4. Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology 2020;158:215-25.e6.
5. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-28.
6. Kanwal F, Kramer J, Li L, Dai J, Natarajan Y, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in non-alcoholic fatty liver disease. Hepatology 2020;71:808-19.
7. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
8. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.
9. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
10. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
11. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8.
12. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2019;16:617-30.
13. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 2019;70:1437-42.
14. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 2015;64:820-9.
15. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996;348:625-6.
16. Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, et al. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol 2003;39:253-61.
17. Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A, Zakaria MK, et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol 2014;20:10238-48.
18. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
19. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:144-52.
20. Jiang T, Liu M, Wu J, Shi Y. Structural and biochemical analysis of Bcl-2 interaction with the hepatitis B virus protein HBx. Proc Natl Acad Sci U S A 2016;113:2074-9.
21. Niu Y, Xu M, Slagle BL, Huang H, Li S, et al. Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis. Hepatology 2017;65:893-906.
22. Jegal ME, Jung SY, Han YS, Kim YJ. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. BMB Rep 2019;52:330-5.
23. Li Y, Fu Y, Hu X, Sun L, Tang D, et al. The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis 2019;10:405.
24. Lee S, Kim W, Ko C, Ryu WS. Hepatitis B virus X protein enhances Myc stability by inhibiting SCF(Skp2) ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis. Oncogene 2016;35:1857-67.
25. Wang J, Li N, Huang ZB, Fu S, Yu SM, et al. HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma. Oncogene 2019;38:6696-710.
26. He B, Peng F, Li W, Jiang Y. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling. J Cell Biochem 2019;120:2908-18.
27. Lin X, Zuo S, Luo R, Li Y, Yu G, et al. HBX-induced miR-5188 impairs FOXO1 to stimulate beta-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. Theranostics 2019;9:7583-98.
28. Chen SL, Zhang CZ, Liu LL, Lu SX, Pan YH, et al. A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma. Cancer Res 2019;79:534-45.
29. Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, et al. Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J Pathol 2017;243:176-92.
30. Bai X, Jia JA, Fang M, Chen S, Liang X, et al. Deep sequencing of HBV pre-S region reveals high heterogeneity of HBV genotypes and associations of word pattern frequencies with HCC. PLoS Genet 2018;14:e1007206.
31. Huang JT, Liu YJ, Wang J, Xu ZG, Yang Y, et al. Next generation digital PCR measurement of hepatitis B virus copy number in formalin-fixed paraffin-embedded hepatocellular carcinoma tissue. Clin Chem 2015;61:290-6.
32. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004;25:2023-32.
33. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 2014;61:408-17.
34. Li TN, Wu YJ, Tsai HW, Sun CP, Wu YH, et al. Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis. J Pathol 2018;245:502-13.
35. Liu P, Zhang H, Liang X, Ma H, Luan F, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget 2015;6:29048-59.
36. Luan F, Liu B, Zhang J, Cheng S, Zhang B, et al. Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma. Pathol Res Pract 2017;213:1037-42.
37. Zhang R, Real CI, Liu C, Baba HA, Gerken G, et al. Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro. Int J Cancer 2017;141:354-63.
38. Luan F, Liu H, Gao L, Liu J, Sun Z, et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 2009;58:1528-37.
39. Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 2019;157:1518-29.e3.
40. Liu W, Guo TF, Jing ZT, Yang Z, Liu L, et al. Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway. FASEB J 2018;32:3033-46.
41. Liu D, Cui L, Wang Y, Yang G, He J, et al. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity. Hepatology 2016;64:390-404.
42. Xie Q, Fan F, Wei W, Liu Y, Xu Z, et al. Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells. Sci Rep 2017;7:41089.
43. Du J, Liang X, Liu Y, Qu Z, Gao L, et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 2009;16:219-29.
44. Liu W, Lin YT, Yan XL, Ding YL, Wu YL, et al. Hepatitis B virus core protein inhibits Fas-mediated apoptosis of hepatoma cells via regulation of mFas/FasL and sFas expression. FASEB J 2015;29:1113-23.
45. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol 2018;92.
46. Duan M, Hao J, Cui S, Worthley DL, Zhang S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res 2018;28:359-73.
47. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 2016;7:12992.
48. Yang X, Wu L, Lin J, Wang A, Wan X, et al. Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue. Int J Cancer 2017;140:1324-30.
49. Wong DK, Cheng SCY, Mak LL, To EW, Lo RC, et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol 2020;18:449-56.
50. Yan H, Yang Y, Zhang L, Tang G, Wang Y, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology 2015;61:1821-31.
51. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256-64.
52. Li CL, Li CY, Lin YY, Ho MC, Chen DS, et al. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region. Hepatology 2019;69:498-512.
53. Yoo S, Wang W, Wang Q, Fiel MI, Lee E, et al. A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis. BMC Med 2017;15:214.
54. Hama N, Totoki Y, Miura F, Tatsuno K, Saito-Adachi M, et al. Epigenetic landscape influences the liver cancer genome architecture. Nat Commun 2018;9:1643.
55. Ren L, Zeng M, Tang Z, Li M, Wang X, et al. The antiresection activity of the X protein encoded by hepatitis virus B. Hepatology 2019;69:2546-61.
56. Musa J, Li J, Grunewald TG. Hepatitis B virus large surface protein is priming for hepatocellular carcinoma development via induction of cytokinesis failure. J Pathol 2019;247:6-8.
57. Hsieh YH, Chang YY, Su IJ, Yen CJ, Liu YR, et al. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis. J Pathol 2015;236:337-47.
58. Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, et al. Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Front Oncol 2019;9:762.
59. Li T, Weng J, Zhang Y, Liang K, Fu G, et al. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma. Cell Death Dis 2019;10:619.
60. Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391.
61. Kodama T, Yi J, Newberg JY, Tien JC, Wu H, et al. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci U S A 2018;115:e10417-26.
62. Ye J, Li TS, Xu G, Zhao YM, Zhang NP, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res 2017;77:5287-300.
63. Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, et al. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J Clin Invest 2018;128:1010-25.
64. Inoue-Yamauchi A, Itagaki H, Oda H. Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. Carcinogenesis 2018;39:28-35.
65. Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, et al. A regulatory role of apoptosis antagonizing transcription factor in the pathogenesis of nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatology 2019;69:1520-34.
66. He Y, Hwang S, Cai Y, Kim SJ, Xu M, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology 2019;70:1150-67.
67. Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019;17:135.
68. Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Camma C, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18:935-44.e3.
69. Tepper CG, Dang JHT, Stewart SL, Fang DM, Wong KA, et al. High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 2018;124:1583-9.
70. Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, et al. Interferon lambda 4 rs368234815 TT>deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology 2017;66:1885-93.
71. Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, et al. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2017;102:2660-9.
72. Cheng YW, Chen KW, Kuo HC, Kuo CH, Lin WH, et al. Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes. Int J Obes (Lond) 2019;43:2469-79.
73. Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128-45.
74. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
75. Yan W, Liu X, Ma H, Zhang H, Song X, et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 2015;64:1593-604.
76. Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebosse F, et al. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol 2019;71:1086-98.
77. Bility MT, Cheng L, Zhang Z, Luan Y, Li F, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014;10:e1004032.
78. Cheng X, Xia Y, Serti E, Block PD, Chung M, et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology 2017;66:1779-93.
79. Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 2016;44:1204-14.
80. Chen J, Xu W, Chen Y, Xie X, Zhang Y, et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type i interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J Virol 2017;91.
81. Zang M, Li Y, He H, Ding H, Chen K, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Biochim Biophys Acta Mol Basis Dis 2018;1864:3759-70.
82. de Oliveira S, Houseright RA, Graves AL, Golenberg N, Korte BG, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol 2019;70:710-21.
83. Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019;25:641-55.
84. Eckert C, Klein N, Kornek M, Lukacs-Kornek V. The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. Front Immunol 2015;6:179.
85. Walenbergh SM, Houben T, Hendrikx T, Jeurissen ML, van Gorp PJ, et al. Weekly treatment of 2-hydroxypropyl-beta-cyclodextrin improves intracellular cholesterol levels in LDL receptor knockout mice. Int J Mol Sci 2015;16:21056-69.
86. Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012;57:141-9.
87. Alisi A, Carpino G, Oliveira FL, Panera N, Nobili V, et al. The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications. Mediators Inflamm 2017;2017:8162421.
88. Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, et al. Lipotoxic hepatocyte-derived exosomal mir-192-5p activates macrophages via Rictor/Akt/FoxO1 signaling in NAFLD. Hepatology 2019. Epub ahead of print. doi: 10.1002/hep.31050
89. Luo X, Li H, Ma L, Zhou J, Guo X, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology 2018;155:1971-84.e4.
90. Yang F, Yu X, Zhou C, Mao R, Zhu M, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog 2019;15:e1007690.
91. Fang Z, Li J, Yu X, Zhang D, Ren G, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis b surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol 2015;195:4873-83.
92. Yu Z, Gao YQ, Feng H, Lee YY, Li MS, et al. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut 2014;63:1793-804.
93. Zhou J, Liu M, Sun H, Feng Y, Xu L, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 2018;67:931-44.
94. Sun H, Yang W, Tian Y, Zeng X, Zhou J, et al. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat Commun 2018;9:5214.
95. Tsunashima H, Tsuneyama K, Moritoki Y, Hara M, Kikuchi K. Accumulated myeloid-derived suppressor cells demonstrate distinct phenotypes and functions in two non-alcoholic steatohepatitis mouse models. Hepatobiliary Surg Nutr 2015;4:313-9.
96. Yao L, Abe M, Kawasaki K, Akbar SM, Matsuura B, et al. Characterization of liver monocytic myeloid-derived suppressor cells and their role in a murine model of non-alcoholic fatty liver disease. PLoS One 2016;11:e0149948.
97. Pallmer K, Oxenius A. Recognition and regulation of T cells by NK cells. Front Immunol 2016;7:251.
98. Biron CA, Altfeld M. Is there natural killer cell memory and can it be harnessed by vaccination? Can natural killer and CD8 T cells switch jobs? Cold Spring Harb Perspect Biol 2018;10.
99. Harmon C, Robinson MW, Fahey R, Whelan S, Houlihan DD, et al. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver. Eur J Immunol 2016;46:2111-20.
100. Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, et al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep 2016;6:26157.
101. Ju Y, Hou N, Meng J, Wang X, Zhang X, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 2010;52:322-9.
102. Li H, Zhai N, Wang Z, Song H, Yang Y, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut 2018;67:2035-44.
103. Yang Y, Han Q, Hou Z, Zhang C, Tian Z, et al. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol 2017;14:465-75.
104. Shi J, Zhao J, Zhang X, Cheng Y, Hu J, et al. Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-beta-dependent emperipolesis in HBV cirrhotic patients. Sci Rep 2017;7:44544.
105. Zhong R, Tian J, Fu M, Ma S, Liu L, et al. LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk. Oncogene 2020;39:1944-56.
106. Cepero-Donates Y, Lacraz G, Ghobadi F, Rakotoarivelo V, Orkhis S, et al. Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine 2016;82:102-11.
107. Cuff AO, Sillito F, Dertschnig S, Hall A, Luong TV, et al. The obese liver environment mediates conversion of NK cells to a less cytotoxic ILC1-like phenotype. Front Immunol 2019;10:2180.
108. Amer J, Salhab A, Noureddin M, Doron S, Abu-Tair L, et al. Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease. Hepatol Commun 2018;2:285-98.
109. Tosello-Trampont AC, Krueger P, Narayanan S, Landes SG, Leitinger N, et al. NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology 2016;63:799-812.
110. Li Y, Tang L, Guo L, Chen C, Gu S, et al. CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J Hepatol 2020;72:420-30.
111. Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 2018;128:4573-87.
112. Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest 2018;128:4588-603.
113. Kim HD, Song GW, Park S, Jung MK, Kim MH, et al. Association between expression level of PD1 by tumor-infiltrating CD8(+) T cells and features of hepatocellular carcinoma. Gastroenterology 2018;155:1936-50.e17.
114. Wang X, He Q, Shen H, Xia A, Tian W, et al. TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol 2019;71:731-41.
115. Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017;169:1342-56.e16.
116. Kim GA, Lim YS, Han S, Choi J, Shim JH, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 2018;67:945-52.
117. Ghazarian M, Revelo XS, Nohr MK, Luck H, Zeng K, et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol 2017;2:pii: eaai7616.
118. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017;551:340-5.
119. Meng F, Zhen S, Song B. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity. APMIS 2017;125:743-51.
120. Wang X, Dong Q, Li Q, Li Y, Zhao D, et al. Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. Gastroenterology 2018;154:2222-36.
121. Publicover J, Gaggar A, Jespersen JM, Halac U, Johnson AJ, et al. An OX40/OX40L interaction directs successful immunity to hepatitis B virus. Sci Transl Med 2018;10.
122. Jacobi FJ, Wild K, Smits M, Zoldan K, Csernalabics B, et al. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. J Hepatol 2019;70:1103-13.
123. Walker CM, Lemon SM. Getting the skinny on CD4(+) T cell survival in fatty livers. Immunity 2016;44:725-7.
124. Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development. Cell Death Dis 2018;9:620.
125. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016;531:253-7.
126. Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 2015;62:87-100.
128. Zhang S, Zhao J, Zhang Z. Humoral immunity, the underestimated player in hepatitis B. Cell Mol Immunol 2018;15:645-8.
129. Poonia B, Ayithan N, Nandi M, Masur H, Kottilil S. HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis. Sci Rep 2018;8:15296.
130. Tout I, Gomes M, Ainouze M, Marotel M, Pecoul T, et al. Hepatitis B virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells. J Immunol 2018;201:2331-44.
131. Schwenger KJP, Chen L, Chelliah A, Da Silva HE, Teterina A, et al. Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with nonalcoholic fatty liver disease. Int J Mol Med 2018;42:2229-37.
132. Zhang F, Jiang WW, Li X, Qiu XY, Wu Z, et al. Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells. J Dig Dis 2016;17:464-74.
133. Bruzzi S, Sutti S, Giudici G, Burlone ME, Ramavath NN, et al. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Free Radic Biol Med 2018;124:249-59.
134. Zhang JC, Chen WD, Alvarez JB, Jia K, Shi L, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol Sin 2018;39:1693-8.
135. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
136. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol 2019;71:543-52.
137. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.
138. Pishvaian MJ, Lee MS, Ryoo BY, Stein S, Lee KH, et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol 2018;29:viii718-9.
139. Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma. Available from: https://www.roche.com/media/releases/med-cor-2019-10-21.htm [Last accessed on 14 Apr 2020].
140. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol 2020;72:342-52.
141. Tang ZS, Hao YH, Zhang EJ, Xu CL, Zhou Y, et al. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep 2016;14:1107-16.
142. Yin Y, Wu C, Song J, Wang J, Zhang E, et al. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One 2011;6:e22524.
143. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494-503.
144. Wang X, He Q, Shen H, Lu XJ, Sun B. Genetic and phenotypic difference in CD8(+) T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. J Med Genet 2019;56:18-21.
145. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
146. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
147. Kelley RK, Abou-Alfa GK, Bendel JC, Kim TY, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol 2017;35.
148. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl J Med 2013;368:1509-18.
149. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 2014;371:1507-17.
150. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018;36:2267.
151. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014;20:6418-28.
152. Wu X, Luo H, Shi B, Di S, Sun R, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther 2019;27:1483-94.
153. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20:119-22.
154. Oelsner S, Waldmann A, Billmeier A, Roder J, Lindner A, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer 2019;145:1935-45.
155. Chu J, Deng Y, Benson DM, He S, Hughes T, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;28:917-27.
156. Xiao L, Cen D, Gan H, Sun Y, Huang N, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther 2019;27:1114-25.
